Literature DB >> 31541402

Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population.

Ren Zhang1, Ming Chen1, Tao-Tao Liu2, Jie-Jiu Lu1, Chun-le Lv1.   

Abstract

BACKGROUND: Most of the current published population pharmacokinetic (PopPK) models are based on serum creatinine, but we often encounter an underestimation of its concentration in our clinical work. Therefore, we established a cystatin C-based model of vancomycin.
OBJECTIVES: The purpose of this study was to externally verify the PopPK model of vancomycin based on the glomerular filtration rate (GFR) estimated by serum cystatin C in our previous study and to compare the prediction performance of cystatin C (Cys C) and serum creatinine (SCR)-based models.
METHODS: The external data set consists of adults receiving vancomycin treatment at The First Affiliated Hospital of Guangxi Medical University. We summarized and restored published models based on serum creatinine values from the literature and used our external data set for initial screening. Visual and external verifications were used to further select candidate models for comparison. The mean prediction error (ME), mean absolute error (MAE) and root mean squared error (RMSE) were the primary outcomes for the overall comparison. Group comparisons of patients with different glomerular filtration rates (GFRs), ages and body mass index (BMI) levels were obtained by the Bayesian method.
RESULTS: A total of 156 patients with 233 samples were collected as an external data set. Sixteen published models were summarized and restored. After screening, four candidate models suitable for the external data set were finally obtained for comparison. The cystatin C-based model has a smaller ME value in the overall comparison. In the group comparison, serum creatinine-based models were underestimated in the prediction for patient groups with age ≥ 60 years, abnormal BMI values and GFR < 90 ml/min/1.73 m2, for which the cystatin C-based model could solve this problem.
CONCLUSION: After comparison, we suggest that cystatin C is a superior renal function marker to serum creatinine for vancomycin PopPK models.

Entities:  

Year:  2020        PMID: 31541402     DOI: 10.1007/s13318-019-00578-4

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  51 in total

1.  Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy.

Authors:  Timothy J Pianta; John W Pickering; Lena Succar; Melvin Chin; Trent Davidson; Nicholas A Buckley; Fahim Mohamed; Zoltan H Endre
Journal:  Kidney Blood Press Res       Date:  2017-03-17       Impact factor: 2.687

2.  Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society.

Authors:  Zhi-Kang Ye; Yao-Long Chen; Ken Chen; Xiang-Lin Zhang; Guan-Hua Du; Bei He; Da-Kui Li; You-Ning Liu; Ke-Hu Yang; Ying-Yuan Zhang; Suo-Di Zhai
Journal:  J Antimicrob Chemother       Date:  2016-07-11       Impact factor: 5.790

3.  A Prospective Multicenter Clinical Observational Study on Vancomycin Efficiency and Safety With Therapeutic Drug Monitoring.

Authors:  Xiaoyu Liang; Yaxing Fan; Minjie Yang; Jing Zhang; Jufang Wu; Jicheng Yu; Jinhao Tao; Guoping Lu; Huifang Zhang; Ruilan Wang; Xiaoxing Wen; Huayin Li; Fengying Zhang; Jingqin Hang; Lihua Shen; Zhongwei Zhang; Qionghua Lin; Fengming Fu; Shengbin Wu; Bo Shen; Weifeng Huang; Chunkang Chang; Hong Zhang; Qiwei Huang; Yifan Shi; Hong Ren; Qing Yuan; Xiaolian Song; Xuming Luo; Hong Zhang
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

4.  Corticosteroids Significantly Increase Serum Cystatin C Concentration without Affecting Renal Function in Symptomatic Heart Failure.

Authors:  Jian-Long Zhai; Ning Ge; Yuzhi Zhen; Qingzhen Zhao; Chao Liu
Journal:  Clin Lab       Date:  2016       Impact factor: 1.138

5.  Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.

Authors:  Elizabeth D Hermsen; Monica Hanson; Jayashri Sankaranarayanan; Julie A Stoner; Marius C Florescu; Mark E Rupp
Journal:  Expert Opin Drug Saf       Date:  2010-01       Impact factor: 4.250

6.  Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens.

Authors:  Wei-Wei Lin; Wei Wu; Zheng Jiao; Rong-Fang Lin; Chang-Zhen Jiang; Pin-Fang Huang; Yi-Wei Liu; Chang-Lian Wang
Journal:  Eur J Clin Pharmacol       Date:  2015-10-01       Impact factor: 2.953

7.  Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.

Authors:  Jason A Roberts; Fabio Silvio Taccone; Andrew A Udy; Jean-Louis Vincent; Frédérique Jacobs; Jeffrey Lipman
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

8.  Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.

Authors:  Susanna E Medellín-Garibay; Belén Ortiz-Martín; Aída Rueda-Naharro; Benito García; Silvia Romano-Moreno; Emilia Barcia
Journal:  J Antimicrob Chemother       Date:  2015-11-14       Impact factor: 5.790

9.  Estimation of safe and effective dose of vancomycin in MRSA-infected patients using serum cystatin C concentrations.

Authors:  Yu-chun Chen; Jia-fu Feng; Bing Li; Ling Zhang; Yu-wei Yang
Journal:  Int J Clin Pharmacol Ther       Date:  2013-03       Impact factor: 1.366

10.  Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study.

Authors:  Erin N Frazee; Andrew D Rule; Sandra M Herrmann; Kianoush B Kashani; Nelson Leung; Abinash Virk; Nikolay Voskoboev; John C Lieske
Journal:  Crit Care       Date:  2014-05-29       Impact factor: 9.097

View more
  4 in total

1.  Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.

Authors:  Yu Cheng; Chen-Yu Wang; Zi-Ran Li; Yan Pan; Mao-Bai Liu; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

2.  Is Cystatin C Good Enough as a Biomarker for Vancomycin Dosing: A Pharmacokinetic Perspective.

Authors:  Guo Yu; Guo-Fu Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

3.  Improved equations to estimate GFR in Chinese children with chronic kidney disease.

Authors:  Ying Tang; Ling Hou; Tingting Sun; Shanping Li; Junli Cheng; Dan Xue; Xiuli Wang; Yue Du
Journal:  Pediatr Nephrol       Date:  2022-04-25       Impact factor: 3.714

4.  Diagnostic Value of Multiple Serum Biomarkers for Vancomycin-Induced Kidney Injury.

Authors:  Sang-Mi Kim; Hyun-Seung Lee; Min-Ji Kim; Hyung-Doo Park; Soo-Youn Lee
Journal:  J Clin Med       Date:  2021-10-27       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.